focus -WSS

focus

author：leisure time 2025-09-29 01:35:28 - browse：63

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CMS got Medicare Advantage quality rating wrong, judge rules

focus

WSS

BD to buy Edwards patient monitoring unit for $4.2 billion

STAT wants to know your pick for a great summer read or listen

Scientists successfully use ultrasound imaging to map brain activity

Prosthetic arm enables patients to feel the objects they grip

Childbirth

Startling documents reveal new facets of Sacklers' opioid empire

Wikipedia

focus

focus

Hepatitis C has a cure — but many Americans still lack access to it

Fight over Supreme Court dialysis ruling puts kidney patients at risk

23andMe had bad news about my health. I wish a person had delivered it

Finland to offer bird flu vaccine to select groups of people, a possible global first

Bright Health sells Medicare Advantage business to Molina

Senators tussle over abortion against the backdrop of a presidential campaign

Medical records are filled with copy

Data don't support strong claims for Covid

Tori Bowie and the unacceptable rates of Black maternal death

Elevance PBM president out as customers face prescription chaos

focus

Latest bird flu infection made farmworker sicker than earlier cases

Addiction doctors spar with methadone clinics over legislation

David Sabatini, ex

Illumina board agrees to spin off Grail, as divestment plans proceed

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Stigma and the return of syphilis

hotspot

focus

leisure time

Wikipedia